ABSTRACT
In Morocco, development of generic drugs, which are copies of original drugs, is not as fast as expected since accession to prescribers, which is essential to the development of these drugs, is still not well established. This report is intended to describe constraints that are behind this reluctance to prescribe these innovative products in public hospitals on the Rabat / Salé Wilaya. The study is based on administrated questionnaires to 91 medical specialists. Collated data were supported by results from interviews with officials at the National Laboratory of Drug Control and the Department of Pharmacy, responsible of hospital pharmacies and medical representatives. Quantitative analysis has been carried out by SPSS [version: 17.0] and Excel software, Among the salient findings, the fact that 83% of physicians suspect the quality of generic drugs and 75% of them believe that the requirement for bioequivalence study is essential to prove their quality. 75% of participants felt that the generic present a higher potential risk following their administration and 82% attest of their therapeutic failure after use. Only 21% of the participants to the study are opting for generic drugs in their prescriptions with 80% of them not adhering to the strategy of the Ministry of Health by considering it as an infringement to their professional freedom. This study highlights the key elements to allow building the National drug policy in order to ensure rational use of medicines and increase the prevalence of generic drugs prescribing. The generic policy, beside the consumer role, is an integration of many parameters as well as the action of the various actors of the health sector. Achieving an equilibrated policy is to combine all these elements and actions responding to patient's needs without overlooking the interests of different parties